ストックスクリーナーアプリを入手
30.29
2.16%
0.64
プレマーケット:
30.65
0.36
+1.19%
前日終値:
$29.65
開ける：
$30
24時間の取引高:
1.88M
Relative Volume:
0.86
時価総額：
$3.52B
収益：
-
当期純損益:
$-472.34M
株価収益率:
-7.306
EPS:
-4.1459
ネットキャッシュフロー:
$-340.33M
1週間 パフォーマンス:
+9.15%
1か月 パフォーマンス:
+0.07%
6か月 パフォーマンス:
-11.69%
1年 パフォーマンス:
+14.60%
1日の値動き範囲:
$29.60
$31.27
1週間の範囲:
$27.16
$31.27
52週間の値動き範囲:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
30.29 | 3.44B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-29 | 開始されました | Canaccord Genuity | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
VKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Viking Therapeutics Adds New CMO As Pipeline Progress And Valuation Scrutinized - Sahm
Is Viking’s New CMO Appointment Reframing the VK2735 Investment Case for Viking Therapeutics (VKTX)? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
VKTX News | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Is Viking Therapeutics Stock Going to $100? - AOL.com
Viking Therapeutics CMO Hire Puts Spotlight On Pipeline Progress And Valuation - Yahoo Finance
VKTX Stock Price, Quote & Chart - ChartMill
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer - Contract Pharma
Viking Therapeutics (VKTX) Appoints New Chief Medical Officer - GuruFocus
Viking Therapeutics Appoints Hubert C. Chen, M.D., as Chief Medical Officer - marketscreener.com
Viking Therapeutics appoints Hubert Chen as chief medical officer By Investing.com - Investing.com Nigeria
Viking Therapeutics Appoints Hubert Chen as Chief Medical Officer - citybiz
Viking Therapeutics appoints Hubert Chen as chief medical officer - Investing.com
Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer - TradingView
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - PR Newswire
Why 1 Wall Street analyst thinks Viking Therapeutics stock could soar 188% - MSN
VKTX eyes worst week since November as trial data looms — Wall Street still sees 200% upside - MSN
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock - AOL.com
Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks - NAI500
Viking Therapeutics, Inc. (VKTX) falls more steeply than broader market: What investors need to know - MSN
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven (VKTX) - Seeking Alpha
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
Why (VKTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Current ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Asset turnover of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Basic earnings per share (basic EPS) of Viking Therapeutics, Inc. – XETR:1VT - TradingView
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
Viking Therapeutics, Inc. Revenue Breakdown – XETR:1VT - TradingView
Viking Therapeutics, Inc. Cash Flow – XETR:1VT - TradingView
Viking Therapeutics, Inc. Balance Sheet – XETR:1VT - TradingView
Viking Therapeutics, Inc. Statistics – XETR:1VT - TradingView
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Obesity Drug Progress Draws Investor Attention - simplywall.st
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
InvestingPro’s overvalued call on Viking Therapeutics saves investors 41% By Investing.com - Investing.com
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jan 05 '26 |
Sale |
32.90 |
57,661 |
1,896,969 |
189,891 |
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):